far-1 Antibody

What is FAR1 protein and why is it important in research?

FAR1 (fatty acyl-CoA reductase 1) is a 59.4kDa protein essential for the reduction of fatty acids to fatty alcohols, a process required for monoesters synthesis. It is also known by several other names including MLSTD2, PFCRD, SDR10E1, and male sterility domain-containing protein 2. FAR1 serves as a rate-limiting enzyme in plasmalogen synthesis, making it significant in lipid metabolism research. The protein is primarily localized to peroxisomes and plays a crucial role in maintaining cellular lipid homeostasis. Research on FAR1 has implications for understanding disorders related to peroxisomal function and lipid metabolism .

What types of FAR1 antibodies are available for research applications?

Multiple types of FAR1 antibodies are available from various suppliers for research purposes. These include:

• Polyclonal antibodies (particularly rabbit-derived)

• Monoclonal antibodies

• Conjugated antibodies (including APC-conjugated options)

• Unconjugated antibodies (most common)

These antibodies demonstrate reactivity with various species including human, mouse, rat, and in some cases, Arabidopsis samples. They come in different quantities ranging from 25μl to 100μl or more, with concentration specifications varying by manufacturer .

What are the common applications for FAR1 antibodies in research?

FAR1 antibodies are utilized in multiple experimental applications including:

These applications allow researchers to detect, quantify, and localize FAR1 protein in various experimental contexts. The specific dilution recommendations should be verified with the manufacturer's documentation for optimal results .

How can I confirm the specificity of a FAR1 antibody?

To confirm the specificity of a FAR1 antibody, implement a multi-step validation protocol:

• Positive and negative controls: Use cell lines known to express FAR1 (such as Daudi) as positive controls and those with minimal expression (such as HepG2) as negative controls.

• Western blot analysis: Verify that the antibody detects a band at the expected molecular weight (calculated 59kDa, though observed at approximately 55kDa).

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide prior to application in your experiment. Specific signal should be significantly reduced or eliminated.

• Knockout/knockdown validation: If possible, test the antibody in FAR1 knockout or knockdown samples to confirm specificity.

• Cross-reactivity testing: Evaluate potential cross-reactivity with related proteins, particularly FAR2, which shares structural similarities with FAR1 .

What are the optimal fixation and permeabilization conditions for FAR1 immunofluorescence in peroxisomal studies?

When conducting immunofluorescence studies of FAR1 in peroxisomes, optimization of fixation and permeabilization is critical due to FAR1's membrane association:

• Fixation method: 4% paraformaldehyde for 15-20 minutes at room temperature preserves peroxisomal morphology while maintaining FAR1 epitope accessibility.

• Permeabilization approach: Due to FAR1's peroxisomal localization, a dual permeabilization approach is recommended:

  • Initial treatment with 0.1-0.2% Triton X-100 (5 minutes)

  • Followed by 0.1% saponin in blocking buffer during antibody incubation

• Blocking conditions: 3-5% BSA or normal serum in PBS with 0.1% saponin for 1 hour at room temperature.

• Co-staining considerations: For co-localization studies, pair FAR1 antibodies with established peroxisomal markers such as PMP70, Pex3p, Pex14p, or PTS1-containing proteins.

This methodology optimizes detection while preserving the structural integrity of peroxisomes, allowing accurate assessment of FAR1 localization and distribution .

How can I design experiments to investigate FAR1's role as a rate-limiting enzyme in plasmalogen synthesis?

To experimentally investigate FAR1's rate-limiting role in plasmalogen synthesis, implement the following research design:

• Expression manipulation strategies:

  • Overexpression of wild-type FAR1

  • Expression of stabilized FAR1 mutants (particularly those with mutations in the C-terminal membrane-flanking region)

  • siRNA or CRISPR-mediated knockdown of FAR1

• Plasmalogen level assessment methods:

  • Liquid chromatography-mass spectrometry (LC-MS) for quantitative analysis

  • Incorporation of radiolabeled precursors to track synthesis rates

  • Thin-layer chromatography for initial screening

• Key controls:

  • Parallel manipulation of FAR2 for specificity assessment

  • Measurement of other lipid species to confirm pathway specificity

  • Time-course studies to distinguish direct vs. secondary effects

• Functional validation:

  • Rescue experiments in knockdown cells

  • Enzyme activity assays with recombinant FAR1

  • Correlation between protein levels (by Western blot) and plasmalogen synthesis rates

This experimental framework enables robust assessment of FAR1's rate-limiting role while accounting for regulatory feedback mechanisms that might compensate for experimental manipulations .

What considerations should be made when designing antibodies targeting specific epitopes within FAR1?

When designing antibodies targeting specific epitopes within FAR1, consider these methodological approaches:

• Epitope selection strategy:

  • Target disordered regions within FAR1 for increased accessibility

  • Utilize bioinformatic tools to identify immunogenic sequences

  • Consider evolutionary conservation if cross-species reactivity is desired

  • Avoid transmembrane domains and regions involved in substrate binding

• Rational design approach:

  • Identify peptide sequences complementary to the target epitope

  • Graft these complementary peptides onto CDR loops (particularly CDR3) of a stable antibody scaffold

  • Consider a single domain antibody scaffold tolerant to peptide grafting

• Scaffold selection considerations:

  • Human heavy chain variable (VH) domain that remains stable without a light chain

  • Scaffolds demonstrating tolerance to mutations in CDR3

  • Structures allowing good expression in bacterial systems

• Validation methodology:

  • ELISA testing with increasing concentrations of the designed antibody

  • Far-UV circular dichroism spectroscopy to confirm structural integrity

  • Functional binding assays to verify epitope-specific recognition

This rational design strategy enables the development of antibodies targeting virtually any chosen epitope within FAR1, including those that may be weakly immunogenic or difficult to target with conventional antibody production techniques .

Why might I observe a discrepancy between the calculated (59kDa) and observed (55kDa) molecular weight of FAR1 in Western blots?

The discrepancy between calculated (59kDa) and observed (55kDa) molecular weight of FAR1 in Western blots can result from several factors:

• Post-translational modifications:

  • Proteolytic processing of FAR1 may occur during peroxisomal import

  • Removal of targeting sequences after localization

  • Differential glycosylation states between theoretical predictions and actual cellular processing

• Protein structure influence:

  • Compact tertiary structure may cause faster migration

  • Hydrophobic regions can bind more SDS, affecting migration

• Experimental variables to investigate:

  • Sample preparation methods (different lysis buffers may affect observed size)

  • Gel percentage and running conditions

  • Sample heating conditions (excessive heating can cause aberrant migration)

  • Different cell/tissue types may process FAR1 differently

• Validation approaches:

  • Use recombinant FAR1 protein as a size standard

  • Perform mass spectrometry to confirm protein identity

  • Test multiple antibodies targeting different epitopes

  • Employ knockout/knockdown controls to verify band specificity

This discrepancy is a common phenomenon in membrane-associated proteins like FAR1 and does not necessarily indicate antibody non-specificity .

What strategies can be employed to optimize FAR1 antibody performance in Western blotting applications?

To optimize FAR1 antibody performance in Western blotting, implement these methodological refinements:

• Sample preparation optimization:

  • Include protease inhibitors to prevent degradation

  • For peroxisomal proteins like FAR1, use specialized lysis buffers containing 0.1-0.5% Triton X-100 or NP-40

  • Sonicate briefly to ensure complete membrane disruption

  • Centrifuge at 10,000g for 10 minutes to remove cellular debris

• Blocking and antibody incubation:

  • Test multiple blocking agents (5% BSA often superior to milk for phospho-proteins)

  • Extend primary antibody incubation to overnight at 4°C

  • Optimize antibody concentration through titration (typical range: 1:500 - 1:2000)

  • Add 0.05% Tween-20 to reduce background

• Signal detection enhancements:

  • Consider enhanced chemiluminescence (ECL) substrates for increased sensitivity

  • Optimize exposure times to prevent saturation

  • Use fluorescent secondary antibodies for more quantitative analysis

• Positive control incorporation:

  • Include Daudi cell lysate as a positive control

  • HepG2 cell lysate can serve as a negative/low expression control

  • Consider using recombinant FAR1 protein when available

This systematic optimization approach addresses common challenges in detecting membrane-associated proteins like FAR1 while maintaining specificity and minimizing background .

How can I address cross-reactivity concerns between FAR1 and FAR2 antibodies?

Addressing cross-reactivity between FAR1 and FAR2 antibodies requires a systematic approach:

• Epitope analysis:

  • Review immunogen sequences for your antibodies

  • FAR1 antibodies raised against amino acids 1-100 (N-terminal region) typically show lower cross-reactivity than those targeting conserved functional domains

  • Perform sequence alignment between FAR1 and FAR2 to identify regions of high homology

• Experimental validation:

  • Run parallel Western blots with both FAR1 and FAR2 recombinant proteins

  • Perform peptide competition assays with specific immunizing peptides

  • Test antibodies in cell lines with differential expression of FAR1 and FAR2

  • Consider knockout/knockdown controls for definitive validation

• Optimization strategies:

  • Increase antibody dilution to reduce non-specific binding

  • Modify washing stringency (increase salt concentration or detergent)

  • Pre-absorb antibodies with recombinant protein of the cross-reactive partner

  • Consider monoclonal antibodies for higher specificity

• Alternative approaches:

  • Epitope tagging of FAR1 in experimental systems

  • Using orthogonal detection methods (mass spectrometry)

  • Implementing proximity ligation assays for higher specificity detection

How should I interpret variations in FAR1 subcellular localization patterns observed in immunofluorescence studies?

Variations in FAR1 subcellular localization patterns require careful interpretation within the context of peroxisomal biology:

• Pattern classification and significance:

  • Punctate pattern: Typical peroxisomal localization, indicating proper targeting

  • Diffuse cytoplasmic pattern: May indicate impaired peroxisomal import or overexpression artifacts

  • ER-like reticular pattern: Could suggest newly synthesized protein or import machinery defects

  • Nuclear/perinuclear accumulation: Potential mislocalization under cellular stress conditions

• Physiological vs. pathological variations:

  • Cell cycle-dependent changes (quantify in relation to cell cycle markers)

  • Stress-induced alterations (oxidative stress may affect peroxisomal import)

  • Metabolic state influence (lipid loading can affect FAR1 localization)

  • Disease-relevant changes (peroxisomal disorders show characteristic patterns)

• Quantification methodology:

  • Measure colocalization with peroxisomal markers (Pearson's correlation coefficient)

  • Quantify size and number of FAR1-positive puncta

  • Assess relative distribution between compartments

  • Implement machine learning algorithms for unbiased pattern recognition

• Control experiments for validation:

  • Co-staining with established markers (PMP70, Pex14p, catalase)

  • Comparison with other peroxisomal enzymes

  • Manipulation of peroxisomal import machinery (Pex3, Pex19)

  • Drug treatments affecting peroxisomal dynamics (e.g., peroxisome proliferators)

This analytical framework enables distinction between biologically significant localization changes and technical artifacts .

What considerations should be made when comparing FAR1 expression data across different experimental systems and antibodies?

When comparing FAR1 expression data across experimental systems and antibodies, consider these analytical factors:

• Antibody-specific variations:

  • Different epitope recognition can affect apparent expression levels

  • Polyclonal vs. monoclonal antibodies may have different sensitivities

  • Lot-to-lot variations in antibody performance must be normalized

  • Cross-reactivity profiles differ between antibodies

• Experimental system differences:

  • Cell type-specific post-translational modifications

  • Species-specific variations in FAR1 sequence and regulation

  • Expression level differences in various tissues/cell lines

  • Endogenous vs. overexpression systems have distinct dynamics

• Normalization strategies:

  • Use multiple antibodies targeting different epitopes

  • Implement absolute quantification with recombinant protein standards

  • Normalize to total protein rather than single housekeeping genes

  • Consider transcript-level validation (qPCR) in parallel

• Metadata documentation for reproducible analysis:

  • Detailed antibody information (catalog number, lot, dilution)

  • Sample preparation protocols (lysis method, buffer composition)

  • Image acquisition parameters (exposure times, gain settings)

  • Quantification methodology (software, algorithms, thresholds)

This comprehensive approach enables meaningful integration of data from diverse experimental contexts while accounting for technical variables that might otherwise confound interpretation .

How can I distinguish between experimental artifacts and genuine findings when studying FAR1 stability and degradation?

To distinguish experimental artifacts from genuine findings in FAR1 stability studies:

• Protein degradation pathway controls:

  • Include proteasome inhibitors (MG132) and lysosome inhibitors (bafilomycin A1)

  • Monitor both natural and tagged FAR1 when possible

  • Assess half-life under different cellular conditions

  • Compare with known stable and unstable proteins

• Time-course design considerations:

  • Use cycloheximide chase assays with appropriate time points

  • Implement pulse-chase labeling for higher sensitivity

  • Monitor both protein and mRNA levels simultaneously

  • Consider inducible expression systems for controlled studies

• Feedback regulation assessment:

  • Measure plasmalogen levels in parallel with FAR1 stability

  • Test mutant FAR1 versions (particularly C-terminal membrane-flanking region)

  • Manipulate metabolic pathways upstream and downstream of FAR1

  • Assess interaction with regulatory proteins

• Technical artifact elimination:

  • Confirm cell viability throughout experiments

  • Validate antibody specificity under each experimental condition

  • Test multiple cell lysis methods to ensure complete extraction

  • Control for transfection/expression level variations

This methodological framework allows researchers to confidently attribute observed changes in FAR1 stability to biological mechanisms rather than technical artifacts, particularly when studying the relationship between FAR1 stability and cellular plasmalogen levels .

How can rational antibody design approaches be applied to develop FAR1 antibodies for specific research applications?

Rational antibody design offers powerful approaches for developing specialized FAR1 antibodies:

• Complementary peptide grafting methodology:

  • Identify peptide sequences complementary to specific FAR1 epitopes

  • Graft these peptides onto CDR loops (particularly CDR3) of stable antibody scaffolds

  • Use human heavy chain variable (VH) domains that remain stable without light chains

  • Engineer CDRs to optimize binding to structured or disordered epitopes

• Application-specific design strategies:

  • For live-cell imaging: Design antibodies targeting extracellular or accessible domains

  • For conformational studies: Create antibodies recognizing specific protein states

  • For functional inhibition: Target catalytic or interaction domains

  • For degradation studies: Develop antibodies recognizing ubiquitination sites

• Validation methodology:

  • ELISA testing with increasing antibody concentrations

  • Far-UV circular dichroism spectroscopy to confirm structural integrity

  • Functional binding assays verifying epitope-specific recognition

  • Application-specific performance testing

• Advantages over traditional approaches:

  • Ability to target weakly immunogenic epitopes

  • Reduced time and cost compared to conventional screening

  • Higher specificity through rational epitope selection

  • Potential for humanized antibodies with reduced immunogenicity

This rational design approach enables the development of antibodies with precise specificity for virtually any epitope within FAR1, opening new possibilities for studying its structure, function, and regulation .

What are the considerations for using FAR1 antibodies in studying the relationship between plasmalogen synthesis and cellular lipid metabolism?

When using FAR1 antibodies to investigate plasmalogen synthesis and lipid metabolism:

• Experimental design framework:

  • Combine protein-level studies (using FAR1 antibodies) with lipidomic analyses

  • Implement perturbation studies (FAR1 overexpression, knockdown, mutation)

  • Monitor temporal relationship between FAR1 expression and plasmalogen levels

  • Investigate feedback mechanisms regulating FAR1 stability and activity

• Cellular model selection criteria:

  • Primary cells vs. cell lines (consider endogenous FAR1 expression levels)

  • Disease models with altered plasmalogen metabolism

  • Tissue-specific differences in FAR1 regulation

  • Models with manipulatable peroxisome abundance

• Advanced analytical approaches:

  • Correlative light and electron microscopy for ultrastructural studies

  • Live-cell imaging of FAR1 dynamics in response to metabolic changes

  • Proximity labeling to identify FAR1 interaction partners

  • Systems biology integration of proteomics and lipidomics data

• Physiological context considerations:

  • Developmental time points (plasmalogen synthesis varies developmentally)

  • Stress conditions (oxidative stress affects peroxisomal function)

  • Metabolic states (fasting vs. fed conditions)

  • Species-specific differences in plasmalogen metabolism

This comprehensive approach enables mechanistic understanding of how FAR1 functions as a rate-limiting enzyme in plasmalogen synthesis and how this process integrates with broader cellular lipid metabolism .

What emerging applications exist for FAR1 antibodies in disease-related research?

Emerging applications for FAR1 antibodies in disease-related research span multiple fields:

• Neurodegenerative disorders:

  • Investigating plasmalogen deficiency in Alzheimer's and Parkinson's diseases

  • Studying peroxisomal dysfunction in neurodegeneration

  • Examining FAR1 expression patterns in brain tissue

  • Developing therapeutic strategies targeting plasmalogen restoration

• Metabolic diseases:

  • Exploring FAR1's role in lipid metabolism disorders

  • Investigating connections between plasmalogens and insulin resistance

  • Analyzing FAR1 expression in adipose tissue and liver samples

  • Correlating FAR1 activity with metabolic syndrome markers

• Cancer biology:

  • Examining altered lipid metabolism in cancer cells

  • Investigating FAR1 as a potential biomarker

  • Studying peroxisome dysfunction in tumorigenesis

  • Exploring FAR1 inhibition as a therapeutic strategy

• Technical innovations:

  • Development of conformation-specific antibodies

  • Implementation of antibody fragments for improved tissue penetration

  • Creation of bispecific antibodies targeting FAR1 and interacting proteins

  • Application of antibody-drug conjugates for targeted therapy

These emerging applications highlight the expanding role of FAR1 antibodies beyond basic research into translational and clinical domains, particularly as the significance of plasmalogens in various disease processes becomes increasingly recognized .